JP6084207B2 - 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤 - Google Patents

虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤 Download PDF

Info

Publication number
JP6084207B2
JP6084207B2 JP2014510747A JP2014510747A JP6084207B2 JP 6084207 B2 JP6084207 B2 JP 6084207B2 JP 2014510747 A JP2014510747 A JP 2014510747A JP 2014510747 A JP2014510747 A JP 2014510747A JP 6084207 B2 JP6084207 B2 JP 6084207B2
Authority
JP
Japan
Prior art keywords
peptide
linker
psd
cpp
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014510747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514365A5 (enExample
JP2014514365A (ja
Inventor
バク，アナス
ストラムゴー，クレスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koebenhavns Universitet University Of Copenhagen
Original Assignee
Koebenhavns Universitet University Of Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koebenhavns Universitet University Of Copenhagen filed Critical Koebenhavns Universitet University Of Copenhagen
Publication of JP2014514365A publication Critical patent/JP2014514365A/ja
Publication of JP2014514365A5 publication Critical patent/JP2014514365A5/ja
Application granted granted Critical
Publication of JP6084207B2 publication Critical patent/JP6084207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2014510747A 2011-05-13 2012-05-11 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤 Active JP6084207B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161485898P 2011-05-13 2011-05-13
EP11165994 2011-05-13
US61/485,898 2011-05-13
EP11165994.2 2011-05-13
PCT/EP2012/058762 WO2012156308A1 (en) 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Publications (3)

Publication Number Publication Date
JP2014514365A JP2014514365A (ja) 2014-06-19
JP2014514365A5 JP2014514365A5 (enExample) 2015-06-25
JP6084207B2 true JP6084207B2 (ja) 2017-02-22

Family

ID=44367299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510747A Active JP6084207B2 (ja) 2011-05-13 2012-05-11 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤

Country Status (13)

Country Link
EP (1) EP2707014B1 (enExample)
JP (1) JP6084207B2 (enExample)
KR (1) KR102046830B1 (enExample)
CN (1) CN103533949B (enExample)
AU (1) AU2012257774C1 (enExample)
BR (1) BR112013029206B1 (enExample)
CA (1) CA2833515C (enExample)
DK (1) DK2707014T3 (enExample)
ES (1) ES2544573T3 (enExample)
IL (1) IL228893B (enExample)
PL (1) PL2707014T3 (enExample)
SG (1) SG194717A1 (enExample)
WO (1) WO2012156308A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160091980A (ko) 2013-12-01 2016-08-03 유니버시티 오브 코펜하겐 Psd-95의 이량체 억제제의 지방산 유도체
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
US10206973B2 (en) 2014-05-28 2019-02-19 Nono Inc. Chloride salt of TAT-NR2B9c
AU2017422458B2 (en) 2017-07-05 2021-07-15 Biocells (Beijing) Biotech Co., Ltd. Polypeptide pharmaceutically acceptable salt et use thereof
JP7073486B2 (ja) * 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CA3089161A1 (en) * 2018-02-02 2019-08-08 Kobenhavns Universitet Compounds for the treatment of acute brain injury
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN110787284A (zh) * 2019-11-23 2020-02-14 胡书群 一种治疗缺血性脑损伤的混合小肽tat-shc及其应用
US20230048338A1 (en) * 2019-12-20 2023-02-16 PYC Therapeutics Limited Novel cellular delivery methods
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
CA3203688A1 (en) * 2021-01-08 2022-07-14 Jonathan David Garman Plasmin-resistant peptides for improved therapeutic index
TW202306965A (zh) 2021-05-12 2023-02-16 哥本哈根大學 Ｐｓｄ－９５抑制劑及其用途
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
WO2024222819A1 (zh) * 2023-04-26 2024-10-31 深圳信立泰药业股份有限公司 一种psd-95结构域抑制剂、其制备方法及其用途
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
CN118027156B (zh) * 2023-09-07 2024-11-05 湖南中晟全肽生物科技股份有限公司 一种psd-95抑制剂及其用途
WO2025215348A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2007140282A1 (en) 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction

Also Published As

Publication number Publication date
DK2707014T3 (en) 2015-09-14
BR112013029206A2 (pt) 2017-02-14
SG194717A1 (en) 2013-12-30
WO2012156308A1 (en) 2012-11-22
KR102046830B1 (ko) 2019-11-20
AU2012257774A1 (en) 2013-11-07
PL2707014T3 (pl) 2015-12-31
EP2707014A1 (en) 2014-03-19
CA2833515A1 (en) 2012-11-22
EP2707014B1 (en) 2015-06-17
IL228893B (en) 2018-01-31
BR112013029206B1 (pt) 2021-05-04
CN103533949A (zh) 2014-01-22
ES2544573T3 (es) 2015-09-01
AU2012257774B2 (en) 2016-07-28
CN103533949B (zh) 2015-11-25
IL228893A0 (en) 2013-12-31
AU2012257774C1 (en) 2016-11-03
CA2833515C (en) 2017-11-28
JP2014514365A (ja) 2014-06-19
KR20140038435A (ko) 2014-03-28

Similar Documents

Publication Publication Date Title
JP6084207B2 (ja) 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤
CA2862391C (en) Stabilized antiviral fusion helices
JP7213811B2 (ja) 新規なステープルペプチドおよびその使用
JP6032854B2 (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
US20250163115A1 (en) BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
US11975040B2 (en) Plexin binding regulator
JP6143270B2 (ja) マイオスタチン阻害ペプチド
US20190092816A9 (en) Stapled peptides and uses thereof
CN117120459A (zh) 抗感染双环肽配体
US9408888B2 (en) High affinity bivalent helically constrained peptide against cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170124

R150 Certificate of patent or registration of utility model

Ref document number: 6084207

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250